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A Review of the Models of Schizophrenia: And a putative novel, more unified
model
Michael Vogel Bronstein
Washington and Lee University
Abstract
Schizophrenia is a debilitating disease state which causes immense pain to sufferers and to their families. Although
some proximate causes of symptoms of the disease have been identified, no ultimate cause has been uncovered
which can explain all of the symptoms. This paper presents a novel theory of the ultimate cause of some forms of
chronic schizophrenia with the potential to explain many (if not all) symptomologies associated with the disease. In
addition to its explanatory power, this putative model may also give rise to new early diagnostic tools and
treatments for schizophrenia. After the model is fully explained, suggestions for further research to confirm this
model's validity are put forth.

Introduction
Schizophrenia is a disease which is part
of the set of human psychotic disorders and
which effects about 1% of the population
worldwide. This disease has been shown to
have a strong genetic component, with a
heritability of around 80% (Rapoport et. al.,
2005). Although the genetic basis of
schizophrenia is well established, the details
surrounding the specific loci of inheritance
are sparse save that there are likely to be
multiple loci involved instead of just a
single gene (Kopala et. al., 2001). Likewise,
the physiological basis of the onset of
psychosis is unknown (Duncan et. al., 1999).
Despite the lack of ultimate certainty in the
underlying causes of this disease, several
models have been proposed in the literature
thus far.
One such model is the N-Methyl-DAspartate (NMDA) hypothesis of
schizophrenia. NMDA is a specific agonist
for a subset of glutamate receptors called
NMDA receptors, which help to regulate the
membrane potential of the cell (Haack et.
al., 1990). The NMDA model hypothesizes
that the hypofunction of NMDA receptors is
the underlying cause of schizophrenia. This
model was proposed because the actions of
ketamine and phencyclidine (PCP) can both
cause and exacerbate psychotic symptoms

similar to schizophrenia, and both block
NMDA receptor activity. The hypofunction
of NMDA receptors could in theory generate
a pattern of dopaminergic dysregulation
which could in turn further negatively
impact NMDA systems (Laruelle et. al.,
2003). These irregularities in the dopamine
system, which are accounted for in the
proposed theory below, could lead to
decreases in nitric oxide levels because
NMDA receptor stimulation results in
calmodulin mediated increases in nitric
oxide synthase [and in turn nitric oxide]
(Coyle, 2013). Since nitric oxide mediated
vasodilation is central to the theory proposed
in this paper, the above points render the
NMDA hypothesis largely subsumed by the
proposed model. Although the NMDA
hypothesis accounts for several facets of the
schizophrenic disease state, it is inadequate
as it has several shortcomings. For example,
one important shortcoming of the NMDA
model is that it fails to explain the lack of
power of agents that reduce the toxicity of
NMDA antagonists in the treatment of
schizophrenia when used alone (Olney et.
al., 1999). These shortcomings necessitate
the exploration of a second model.
A second model of schizophrenia is the
dopamine hypothesis. This model
hypothesizes that the onset of the disease is
characterized by abnormal dopamine
47
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processes. In its current form, a
hypodopaminergic state occurs in the frontal
regions, causing negative symptoms, while a
hyperdopaminergic state in the ventral
tegmental area results in psychosis (i.e.,
positive symptoms). There are numerous
shortcomings of the dopamine hypothesis,
including a lack of evidence of abnormally
high dopamine levels, along with the low
affinity for dopamine receptor subclasses of
certain anti-psychotics (Duncan et. al.,
1999). Additional shortcomings include the
fact that some anti-psychotics, such as
Haloperidol, actually significantly increase
dopamine receptor binding potential when
used long term (Silvestri et. al., 2000).
Despite these failures, the dopamine theory
is currently still a predominant theory, and is
subsumed by the model proposed in this
paper with modifications which make up for
many of its shortcomings. For example, the
model proposed in this paper includes an
alteration in the ratio of D 1/D2 receptor
activity. This does not necessitate an overall
increase in either dopamine receptors,
metabolites, or dopamine itself. Again, the
shortcomings of the dopamine hypothesis
necessitate the exploration of a third model
of schizophrenia.
A third model of schizophrenia is the
attentional or information processing model
of schizophrenia. This model draws from the
above neurotransmitter models with a focus
on the attentional component of the disease.
Evidence for this model comes from several
sources, including work by Takahashi et. al.
(2010) which states that schizophrenics
cannot
effectively
gate
irrelevant
sensorimotor and cognitive information, and
which shows neural substrates for
accompanying (and perhaps proximately
causal) deficits in mismatch negativity
(MMN) and P3a in schizophrenics. These
neural substrates implicate widespread
attentional network abnormalities in the
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brains of schizophrenics. Further evidence
comes from work by Swerdlow et. al. (2008)
which suggests that, in humans and in mice,
NMDA antagonists can disrupt pre-pulse
inhibition (PPI). Incidentally, PPI is also
reduced following the administration of
phencyclidine (PCP), which is used to create
a model of schizophrenia commonly used in
experimental animals. The information
processing deficits seen in this model can be
accounted for by an alteration in the D 1/D2
receptor activity ratio. Because such an
alteration is incorporated into the proposed
model in this paper, the information
processing model of schizophrenia is
subsumed by the model proposed in this
paper.
A final model of schizophrenia, the PCP
model, is also subsumed by the model
proposed in this paper. The PCP model of
schizophrenia is based on the fact that the
induction of psychosis can be achieved by
administering PCP. This induction of
psychosis may be in part mediated by
cardiovascular system effects of the drug.
This is supported by the fact that rats given
PCP
have
changes
to
their
electrocardiogram completely blocked by
either Haloperidol (an anti-psychotic
effective in treating schizophrenia) or the
vasodilator agent nitroglycerine (Shi & Xu,
1994). This suggests that the efficacy of
Haloperidol in treating schizophrenia is
partially mediated by the ultimate effects of
its administration on the cardiovascular
system (see later explanation of these effects
and the drug's efficacy). This also suggests
that the effects of PCP are in part mediated
by cardiovascular effects. Additional
support for this concept comes from the fact
that in rats nitric oxide (NO) mediates
vasodilation, which is effected by oestrogen
and also is shown to increase after PCP
administration (Palsson et. al., 2010). This
response appears to be compensatory, as it is
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temporally shifted with respect to the
maximum behavioral effects of the drug.
Interestingly, this effect occurs most in the
prefrontal cortex and ventral hippocampus,
two areas implicated in schizophrenia. The
combination of all of the above information
provides further support for the putative
model put forth in this paper by suggesting
the role of cardiovascular deficits having a
role in the ability of PCP to create a model
of schizophrenia in individuals to whom it is
administered. Thus, there is the possibility
that the model which will be proposed in the
subsequent section subsumes the PCP model
of the disease. This potential is supported by
the work of Palsson et. al. (2010), which
states that there is support in their data for
"an interaction between PCP and a stress
response converging on the NO signaling
pathway."
none
of
the
Unfortunately,
neurotransmitter models currently proposed
adequately account for the symptomology,
progression, and treatment of chronic
schizophrenia. Thus it is necessary to
propose a new model which has an
underlying cause not based in
neurotransmission itself and which
integrates the strengths of current
hypotheses while accounting for their
shortcomings. The model proposed in this
paper fulfills this role for chronic forms of
schizophrenia (it does not attempt to account
for more acute forms of the disease). An
outline of the proposed model, as well as
supporting evidence, will be explored in the
next section.
Proposed Model
Several observations in schizophrenics
prompted the model of schizophrenia
proposed here. First of all, although microlevel events occurring in the brains of
schizophrenics would not be detectable with

the spacial resolution of imaging techniques
such as magnetic resonance imaging (MRI),
they may manifest on a macro level as gross
structural abnormalities. Such macro level
abnormalities are apparent in many MRI
studies, including Rupp et. al. (2005).
Secondly, impairments in vasodilation in
schizophrenics have been found in several
studies, including Turenne et. al. (2001) and
Hudson et. al. (1997). Third, schizophrenics
have increased levels of nitric oxide
synthase (NOS, the enzyme which
catabolizes nitric oxide) in the cortex
(Karson et. al., 1995), which may be an
attempt to compensate for impaired
vasodilatory response to nitric oxide (like
that seen in those with oestrogen resistance).
Fourth, schizophrenics respond positively to
treatment with oestrogen (Hafner, 2003),
and tend to have low blood oestrogen levels
(Rossler & Hafner, 1993). Fifth, women
tend to develop symptoms of schizophrenia
during points in the menstrual cycle with
lower oestrogen levels. This effect was so
marked that "menstrual psychosis" was
listed as a separate diagnostic category in
the early 1900s. This effect is mirrored
across the female life cycle, as late onset
schizophrenia (after age 40-45) is much
more prevalent in females than males and is
associated with a loss of ovarian functioning
starting at about the same age (Rossler &
Hafner, 1993). Finally, individuals
with
(including
non-schizophrenics)
oestrogen resistance tend to exhibit deficits
in nitric oxide mediated vasodilatation,
especially in response to ischemic events
These
(Faustini-Fustini et. al., 2009).
considered
when
observations,
simultaneously, suggest a oestrogen
mediated deficiency in vasodilatory
response to ischemic stimuli in
schizophrenics. This deficiency may result
in micro-ischemic events, micro-infarct, and
general functional instability at a micro
circuit level. This may be further
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exacerbated by the impaired glucose
tolerance (IGT) of medication naive first
episode schizophrenics reported by Collins
et. al. (2003) as IGT has been associated
with increased risk of ischemic stroke (e.g.,
in diabetes). This suggestion of microischemic events and micro-infarcts in
schizophrenics, mediated by an oestrogen
influenced deficiency in nitric oxide
mediated vasodilatory response to ischemic
events, forms the core of the novel putative
model proposed here to account for the
deficits and abnormalities seen in chronic
schizophrenia.
This model has surprisingly great
explanatory value as a putative ultimate
cause of some forms of chronic
schizophrenia. For example, the observed
levels of higher neural noise in
schizophrenics can be explained with this
model if there are differential effects of
unstable oxygen supply on D1 vs. D2
receptor systems, as the D 1/D2 activation
ratio is crucial for maintaining stability of
the representations of internal and external
stimuli in local circuits and for optimizing
noise levels in these circuits (Winterer et.
al., 2004). Such differential effects on D1
and D2 receptor activity after ischemia is
seen in Mongolian gerbils, and consists of a
decrease in the number of D2 binding sites
in the striatum along with an accompanying
decrease in D1 receptor affinity which is
more widespread (Chang et. al., 1993). If
these changes generalize to humans, they
provide a putative mechanism for the
alteration in D 1/D2 receptor activity ratio.
Further, since D2 agonists exert
neuroprotective effects in rats by decreasing
neuronal activity levels (O'Neil et. al. 1998),
this change in the number of D2 receptor
binding sites (if it generalizes to humans)
may provide a positive feedback mechanism
for increasing the likelihood of future
ischemic events as decreasing the number of
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D2 binding sites would be the functional
equivalent of a D2 receptor antagonist.
Indeed, such a relationship between
disturbed dopamine production and an
increase in the risk of ischemic stroke is
strongly suggested by the observed increase
in ischemic stroke in Parkinson's disease
patients (Chang et. al., 1993). If this holds in
schizophrenics, it would create a positive
feedback mechanism such that each
ischemic stroke increases the likelihood of
another, thereby ensuring chronically high
neural noise levels in this population.
The increase in neural noise levels
generated in this manner may help to
explain
the
decoupling
between
physiological markers and behavioral
outcomes observed in schizophrenia. One
example of this decoupling is the finding
that larger left temporal lobe volumes were
associated with better odor identification in
controls but not in schizophrenics (Moberg
et. al., 2006). A second example of this
decoupling is the finding by Kayser et. al.
(2010) that olfactory event-related potentials
(ERPs) were substantially less related to
odor intensity and subsequent identification
in schizophrenics (vs. controls). A third
example of this decoupling is the possible
disassociation reported by Manor et. al.
(1999) between attentional allocation
(visual) and eye fixation location in
schizophrenics. A final example of this
decoupling is the fact that the correlation
between olfactory bulb volume and
olfactory abilities in healthy subjects
(independent of age), reported by
Buschhuter et. al. (2008), is not present in
schizophrenics (c.f., Turetsky et. al., 2003).
The wide range of domains in which this
decoupling is found suggests a global level
parameter is disrupted in schizophrenia.
Alterations in levels of neural noise certainly
conform to this suggestion.
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The increase in neural noise levels
generated by the alteration of D 1/D2
receptor activity may also help to explain
the deficits in olfaction present in
schizophrenics, because according to signal
detection theory this should decrease
sensitivity and increase rates of false alarms
of odor presence (i.e., hallucinations). This
increase is consistent with the olfactory
hallucinations experienced by some fourteen
percent of patients (Stevenson, 2013). These
deleterious effects of neural noise on
olfaction should be amplified by causal
fluctuations in blood oxygen level putatively
experienced by schizophrenics, as these may
reduce the reliability of neural responses
further by limiting the resources available to
make the optimal response.
In addition to this explanation of
olfactory deficits, the model put forth in this
paper also explains a second abnormality
which could contribute to the olfactory
deficits in schizophrenia. This abnormality,
identified by Turetsky et. al. (2003), is that
schizophrenics exhibit increased protein
expression of Growth Associated Protein 43
(GAP-43). This suggests that schizophrenic
patients have difficulty establishing or
maintaining synaptic connections between
the olfactory bulb and epithelium. The
unstable oxygen supply assured by the
proposed model would certainly increase the
difficulty in maintaining viable connections
between these two locations, and could thus
help to explain the results found. Since the
olfactory system depends on memory to
compare odors, the high vulnerability of the
hippocampus to ischemic damage would
further mediate deficits in olfaction under
this model. Such damage would also explain
the verbal memory deficit present in
schizophrenia.
The model proposed in this paper would
also account for the attentional deficits that

have been recently more prominently
associated with schizophrenia (e.g.
Swerdlow et. al., 2008; Takahashi et. al.,
2010). Thus, the attentional model of
schizophrenia is subsumed by the proposed
model. This attentional phenotype could be
explained by the fact that attentional
maintenance requires energy, for which a
consistent supply of glucose and oxygen
(both delivered via the blood) are required.
Further, the delusional thinking present in
schizophrenia could be explained by the
putatively increased neural noise levels
combined with a lack of mode two
processing (inducing both erroneous results
and the lack of the depth of reason necessary
to debunk them) in schizophrenics. This
possibility is supported by a study by
Masicampo et. al. (2008), which found that
blood glucose levels manipulated with
lemonade alone could induce processing
level differences (compared to a control
group). It stands to reason that this would
also apply to inconsistent oxygen supply (as
would occur with improper ischemic
vasodilation) in schizophrenics as oxygen is
required for the cellular respiration
necessary to utilize the glucose obtained
from the blood.
In addition to explaining these more
internal deficits, interactions with the larger
environment can be explained using the
proposed model as well. One example of
such an interaction is that between
schizophrenics and nicotine. Many studies
have found that schizophrenics smoke
significantly more packs per day than
controls (e.g. Rupp et. al., 2005). This can
be explained by the putative model plus two
additional factors. The first of these factors
is that schizophrenics tend to have impaired
vasodilation response to nicotinic acid
(formed in the blood after smoking tobacco).
The second factor is that metabolites of
nicotine, such as cotinine, cause vasodilation
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to occur. These factors taken together
suggest that schizophrenics, on average,
would have to smoke more cigarettes to
achieve the vasodilatory results of cigarette
smoking. The proposed model provides the
impetus to smoke in the first place: to
achieve short term alleviation of the
reduction in vasodilation in response to
ischemic stimuli. Unfortunately, it is likely
that long-term, this is maladaptive because
the build-up of carbon monoxide and
dioxide in the blood will create the very
conditions that the patient attempted to
alleviate in the first place (micro-ischemic
events) by lowering the amount of oxygen in
the blood. This effect should become more
pronounced with higher pack-per-day loads.
The above points make it apparent that there
would be a positive feedback loop between
smoking behavior and symptomology in
schizophrenics. This possibility places even
greater importance on controlling for the
effects of smoking when studying
schizophrenia.
In addition to both internal and
behavioral traits of the disease, the proposed
model can help account for the efficacy of
several treatments for schizophrenia. One
such treatment is Haloperidol, an
antipsychotic medication for which there
exists a wide variation in the time it takes to
achieve clinical response (as defined by a
20% reduction in symptomology). Within
this variation, it takes 8 weeks for 90% of
patients to achieve clinical response. This
suggests that long term compensatory
changes mediate the efficacy of this drug
(see below for details on this mechanism).
Despite the large time delay in achieving
efficacy, response to treatment within a
single week is highly predictive of clinical
response at 8 weeks. In fact, only 40% of
those who had not responded after 1 week of
treatment achieved clinical response after
four weeks (Emsley et. al., 2006). This
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suggests the contribution of more short term
mechanisms to the efficacy of Haloperidol
as well.
The short term actions of Haloperidol
are consistent with the proposed model as
Haloperidol is a D2 receptor antagonist
(likewise, many antipsychotics are
dopamine receptor antagonists). In the short
term, Haloperidol would therefore have the
effect of increasing the amount of synaptic
dopamine by blocking the binding of
dopamine to available receptors. Dopamine
has been found to be able to induce
microvascular vasodilation in the brain in an
effect at least partially mediated by D 1/D5
receptors. This is especially so in the
striatum (Choi et. al., 2006). Thus, a
dopamine receptor antagonist (like
Haloperidol)
should
increase
the
vasodilatory effects of dopamine, which
should prove to be neuroprotective. In
schizophrenic males, this effect should be
compounded by the fact that in one third of
the male schizophrenic cohort Haloperidol
causes an increase in oestrogen levels
(Rossler & Hafner, 1993), thus helping to
counteract the problem of a oestrogen
mediated issue in nitric oxide induced
vasodilation. This neuroprotection should
occur by augmenting schizophrenics' poorly
functioning nitric oxide mediated
vasodilatory pathway, and thus increasing
oxygen availability during potential
ischemic events (i.e., helping to prevent
ischemia from occurring).
The long term effects of Haloperidol are
also consistent with the proposed model
because Haloperidol has been shown to
engender an average increase, compared to
the age-corrected baseline values derived
from the eight antipsychotic-naive control
subjects, of 34% in the D2 binding potential
(a combined measure of affinity for a
receptor and receptor density) in a group
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consisting of both novel and traditional
antipsychotic patients (Silvestri et. al.,
2000). This long term D2 receptor activity
up-regulation may well provide the
additional efficacy which causes many
patients to achieve clinical response after
several weeks of treatment. This is
consistent with findings by O'Neil et. al.
(1998) which suggest that increasing D2
activity is neuroprotective in rats (this is
more fully discussed above). This
neuroprotective effect should be further
augmented since sensitivity of D2 receptors
is negatively correlated with amount of
oestrogen present (Hafner et. al., 1991).
Because of this and the fact that
schizophrenics tend to have reduced serum
oestrogen (Rossler et. al. 1993), they should
also exhibit increased dopamine receptor D2
sensitivity. The combination of this
increased sensitivity to D2 activity and its
should
be
highly
up-regulation
neuroprotective. This notion, in confluence
with that in the preceding paragraph,
demonstrate that the proposed model
accounts for both the long term and short
term efficacy of antipsychotics in providing
protection against (short term) and
mitigating the results of (long-term)
oestrogen mediated micro-ischemic events
in schizophrenics.
Haloperidol and other medications used
to treat schizophrenics are also consistent
with the model proposed in this paper
because schizophrenics who are medicated
display a drop in the amount of entropy in
their resting electroencephalogram (EEG)
compared to their pre-medication levels
(Fernandez et. al., 2013). Entropy (when
applied to EEG) measures the predictability
of future EEG activity from previous
activity, with increased entropy indicating a
decrease in the predictive value of this
previous activity. The predictive value of
previous activity should, by definition, be

decreased by increases in the level of neural
noise in the brain of the individual whose
EEG is being recorded (thus increasing
entropy levels). Because of this, entropy is
an indirect measure of the levels of neural
noise in the brain. Therefore, the decrease in
entropy levels in medicated schizophrenics
is consistent with the idea that mechanisms
that induce neural noise increases in the
brains of schizophrenics are causal in
producing the disease's symptomology
because medication decreases both neural
noise levels and symptomology in
schizophrenics.
The model proposed in this paper is also
consistent with the treatment value of a
more recent medication used in the
treatment of schizophrenia, namely
recombinant human Erythropoietin (EPO).
EPO has been shown to improve cognitive
symptoms of schizophrenia and attenuate
progressive gray matter loss in
schizophrenic men when a high dose was
administered weekly (Ehrenreich et. al.,
2010). This is consistent with the model
proposed in this paper because EPO is
widely used as a neuroprotective agent.
Notably for the purposes of this paper, EPO
was successfully used (by the same
researchers) in the prevention of damage
from ischemic stroke for several years
before it was successfully tried as an adjunct
treatment for schizophrenia. The treatment
value of EPO in reducing ischemic stroke
damage, loss of tissue (which could
conceivably result from such damage) in
schizophrenics, and the cognitive symptoms
of schizophrenia establishes a further
correlation between these reduced factors,
which supports the proposed model's
intertwining of them.
A final feature of schizophrenia that can
be explained by this model is the course of
the disease itself. One debate in the literature
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has been whether schizophrenia is simply a
neurodevelopmental disease or is a
neurodegenerative one as well (Duncan et.
al., 1999). The model proposed here
reconciles many of the features of this
debate in the following manner: in this
model, during the initial prodromal period,
symptoms are caused by the instability of
blood oxygen flow to brain areas. This
prodromal period is usually delayed in onset
until adolescence for several reasons. The
first of these is cerebral oxygen demand
(CMRO2) increases with age, peaking at 2130 (Hafkenschiel et. al., 1953). This,
incidentally, includes the range of age of
onset most common for schizophrenia.
Although this study was conducted in
hypertensive patients, they provide
extensive evidence showing that this group
does not differ from normal in CMR02.
levels (and additionally, as will be discussed
later, hypertension occurs often in
schizophrenia). The trend found in this study
suggests that the putative deficits of oxygen
supply to the brain present in schizophrenics
are not severe enough to manifest until
blood oxygen demand (and thus, to a certain
degree, vulnerability to ischemia) increases.
The late age of onset of the disease can also
be explained with evidence from a mouse
model suggesting a higher vulnerability of
white matter to ischemic damage with
increasing age (Baltan et. al., 2008). If this
generalizes to humans, then this would also
help to explain the later onset of the disease
(because ischemia will be less detrimental
earlier in life).
When the prodromal period does begin,
little micro-infarct occurs as a result of the
deficiencies present in schizophrenics
because of the protective effects of brainderived neurotrophic factor (BDNF). This
allows for some progression of the disorder,
but minimal overall effect compared to what
is to come. At this point of dynamic
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equilibrium, gross structural abnormalities
are progressively accrued, increasing the
patients' vulnerability to a causal stressor
over time (hence the high age of formal
onset of the disease). Such a stressor may
upset this dynamic equilibrium as stress has
been shown to decrease BDNF levels
(Bremner, 1999). This effective reduction in
the amount of BDNF protection afforded
neurons would be compounded due to
abnormalities in the expression of BDNF in
schizophrenics reported by Asche et. al.
(2001), such as reduced serum BDNF,
reduced Messenger Ribonucleic Acid
(mRNA) for BDNF, and an allele variant of
BDNF in some patients. At this point, the
formal onset of the disease may occur due to
micro infarct (and increased effects of
ischemia due to accrued structural
abnormalities) in vulnerable areas. This
relatively larger and more sudden
accumulation of damage may account for
the phenomenon of a "schizophrenic break"
[to use a familiar analogy: this situation
mirrors the action of neurons upon one
another in engendering an action potential
where structural changes accrue in the form
of opening and closing ion channels, and
eventually, given a 'causal' stressor, these
changes will overcome the threshold for
firing at the axon hillock, and an action
potential will ensue]. The results of this
break should vary according to the unique
pattern of structural abnormalities accrued
during the prodromal period and the
resulting differing vulnerabilities to
decreased reliability of blood oxygen in
separate areas of the brain. These structural
abnormalities, through their interaction with
individual differences in both the stress of
the disease itself (causing a further reduction
in BDNF) and in the amount of BDNF
suppression caused by this stress, should
determine the chronic nature and the unique
course of the disease in each individual.
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After this schizophrenic break occurs,
the degeneration generally peaks and
symptoms begin to gradually lessen. The
great capacity of humans to adapt to
stressful situations can explain this
phenomenon, as gradually the disease state
becomes less stressful, and thus levels of
BDNF may rebound. This process of
symptom reduction may then be augmented
by long term plasticity of the human brain,
and by the fact that a relatively small
number of new neurons are continuously
generated in the adult brain (Johansson et.
al., 1999). Both of these facts may lead to
adaptations to the damage that has occurred,
and thus a reduction in overall
symptomology. The lack of progression of
the disease after a certain point may also be
attributed to the severity of the micro
ischemia, which may not be severe enough
to effect many areas of the brain. This would
mean that after a period of degeneration, the
disease would cease to progress as it would
have effected all areas within this threshold.
This model of the disease course is
consistent with the findings of Asche et. al.
(2001), which suggest that there is a role of
BDNF in schizophrenia. Further, it is
consistent with the well documented ability
of stress to precipitate the onset of as well as
relapses in schizophrenia. Finally, the micro
ischemia model is also supported by
findings that reduced chances of recovery
occur, along with increased residual
symptoms, after each relapse (Duncan et. al.,
1999), as each relapse signifies a period of
more rapid accrual of damage.
Now that the basic support for this
model has been established, it is worth
exploring several conclusions that follow
from this model. One such logical sequel to
the idea that the symptoms of schizophrenia
are mediated by an oestrogen deficit
resulting in vascular dysfunction is that the
rates of coronary heart disease (CHD)

should be increased in patients over
controls. Indeed, this is the case: a study by
Cohn et. al. (2004) found that the ten year
risk of myocardial infarction is higher in
patients (both male and female, although
only significant for the men) than in a
control population. This risk increase cannot
be explained by the increase in smoking
rates alone, nor can it be explained by
increases in total cholesterol levels. This
suggests that something must be
physiologically abnormal in schizophrenics'
vascular systems, just as the model put forth
here postulates. This is supported further by
findings in many studies that there are
region-specific reductions in blood flow in
the brains of schizophrenics, and that these
correlate with negative symptoms (c.f.,
Interestingly,
Coyle,
the
2013).
schizophrenics studied by Cohn et. al. (all
inpatients) had a two times higher risk for
metabolic syndrome, which includes
hypertension, compared to controls. The
huge increase in the prevalence of this
disorder in this population of people with
the worst symptoms (those who are
inpatients)
among
their
cohort
(schizophrenics) suggests that high blood
pressure makes the symptoms of
schizophrenia worse. This is consistent with
the model of ischemia mediating
schizophrenic symptoms, as high blood
pressure and metabolic syndrome would put
additional strain on an already stressed
cardiovascular system.
Additional support for the idea that
increases in blood pressure are detrimental
to schizophrenics comes from the
combination of the findings of two studies.
The first finding is from a study by
Robertson et. al. (1978), which showed that
caffeine causes mean blood pressure to rise
14/10 mm of mercury one hour after
caffeine ingestion in healthy controls (in
short, caffeine can cause acute blood
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pressure increases). This finding is
augmented by that of Lucas et. al. (1988)
which showed that 10mg/kg of caffeine
administered to schizophrenics worsens
several measures of the presence of
psychosis and increases diastolic blood
pressure in schizophrenics. These two
finding's confluence is consistent with the
idea that increased blood pressure can
worsen schizophrenia symptoms, and thus
provides additional evidence for microischemic events as the proximate cause of
schizophrenic symptoms. Further support
for this (and thus the proposed model)
comes from a recent study by Hallack et. al.
(2013) which found that a single dose of
nitroprusside caused a persistent (for 2
weeks after treatment) and rapid reduction
in symptoms in schizophrenics (Coyle,
2013). Although these results are still being
treated with caution due to the experimental
design, this finding (if sound) is significant
because nitroprusside is used clinically to
reduce blood pressure in hypertensive
individuals. In addition to its ability to cause
a reduction in blood pressure, nitroprusside
can cause vasodilation, thus increasing
cerebral perfusion. This action of
nitroprusside combined with its positive
effect on schizophrenics is also consistent
with the proposed model because it would
allow for increased oxygen supply to the
brain (and thus a reduction in ischemic
events) while helping to ensure vasodilation
when these events occur.
It is important to note that although the
above points offer seem to offer a simple
avenue to treat schizophrenia (namely,
increasing NO levels with treatments such as
nitroprusside), this should be done with
caution for several reasons. The first of these
reasons is that nitric oxide may activate the
Hypothalamic-Pituitary-Adrenal (HPA) axis
(Palsson et. al., 2010). This suggests that the
increases in nitric oxide levels (which may
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in the short term help to compensate for
resistance to the chemical's vasodilatory
effects) which occur in schizophrenics
(Karson et. al., 1995) may actually be
maladaptive long term because this increase
may amplify stress responses. The second of
these reasons is that nitric oxide is
associated with the generation of neurotoxic
reactive oxygen species. As mentioned
above, these cautions may also apply to
treatments targeting NMDA receptors since
activation of these receptors leads to
calmodulin mediated activation of nitric
oxide synthase (Coyle, 2013).
A second consequence of vascular
dysfunction in the brain is that similar
pathology should be seen in the retinas of
schizophrenic patients. This should occur
because there is a large body of evidence
(see Patton et. al., 2005 for a review) which
indicates that the state of the
microvasculature of the retina is indicative
of that in the brain. There is currently a large
amount of evidence for such retinal
pathology in schizophrenics. For example,
82% of the 23 total chronic schizophrenic
patients in a study by Smith et. al. (1997)
had one or more gross ocular abnormalities.
These abnormalities mirror gross structural
changes in the brain, and would be expected
if the vasculature of both systems mimicked
each other (as has been shown) and if the
cause of these changes in the brain was
mediated by vasculatory system
abnormalities (as proposed in this paper).
When examining the fundus (the back of the
eye, including the retina) specifically, 52%
of schizophrenic patients examined
displayed some abnormality, and 46% had
vascular abnormalities in this region
(Vannas et. al., 1961).
This pathology in the retina, is worth
examining in depth because it provides (as
Patton et. al., 2005, indicate) good evidence
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for the possibility that micro-vascular
abnormalities such as those proposed in this
paper's model of schizophrenia can lead to
the functional abnormalities observed in
schizophrenics. This can be demonstrated by
examining the work of Cotton et. al. (1940).
In this study, there was a high degree of
correlation between the clinical status of the
schizophrenic patient and the capacity of the
retinal vascular bed. More exactly, this
correlation was that patients who did not
improve or who deteriorated had a relatively
(to the improving group) small retinal
vascular bed in a high percentage of cases.
In contrast, patients who improved or
recovered had a significantly larger retinal
vascular bed. Further, longer disease
duration was significantly correlated with
lower retinal vascular bed volume (this
appears to be a marker of susceptibility, and
is not a direct result of the disease). These
relationships
were
volume-status
strengthened after correcting for body
volume. If this is mirrored in the brain, this
is consistent with the proposed model (as
lower vascularization density should
increase vulnerability to ischemia by
decreasing net blood flow to the brain with a
given blood pressure). This particular
study's data is especially valuable because
these patients are medication naive (the first
neuroleptic, chlorpromazine, was initially
marketed in the 1950s). In addition to these
structural abnormalities, abnormal retinal
function (paralleling the abnormal function
of the brain) is shown in schizophrenics in
the form of abnormal physiological
measures such as electroretinography.
Interestingly, the severity of these
abnormalities correlates with the severity of
clinical symptoms of schizophrenics
(Balogh et. al., 2008), which is consistent
with the proposed model because it shows
that there is a relationship between vascular
and functional abnormalities in the eyes of

schizophrenics which should be mirrored in
their brains.
A second consequence of the idea that
the symptoms of schizophrenia are mediated
by a deficit of oestrogen is that there should
be a decrease in high density lipoprotein
(HDL) which accompanies the disorder.
This idea follows from the finding of Bush
(1996) that women taking oestrogen
replacement therapy experience an increase
in HDL levels. Thus, a decrease in this
hormone should result in the opposite
phenomenon: a decrease in the level of
HDL. This concept is consistent with the
finding that there is indeed a significant
decrease in HDL among schizophrenics
(Cohn et. al., 2004). This could further
exacerbate the vascular problems underlying
schizophrenia, as HDL is known to help
prevent arterial disease such as
atherosclerosis (Barter, 2005).
To examine a different subtype of
sequelae, a logical sequel to the ischemia
related model of schizophrenia put forth in
this paper is that there should be an
accompanying leakage of fluid into the extra
cellular matrix due to a decrease in
membrane integrity. Also, there should be a
decrease in the total volume of brain tissue
(due to both sub-optimal growth and
possible cell death) in schizophrenics
compared to controls. Evidence consistent
with this phenomenon is found in the
research of Andreasen et. al. (1994), who
state that compared with the controls,
schizophrenia patients had a smaller average
volume of total brain tissue and a greater
average volume of total and ventricular
cerebrospinal fluid (CSF). It stands to reason
that there should be increases in total fluid
volume if fluid is leaking into the extra
cellular matrix. A second corollary to the
idea of ischemia or infarct in schizophrenia
is that there should be evidence of cellular
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atrophy. Such evidence was found by
Oxenstierna et. al. (1984) in the cortex and
vermis on computed tomography (CT) scans
of schizophrenia patients' brains. A third
logical sequel to the idea of increased
vulnerability to ischemia and infarct is that
there should be a decrease in life expectancy
that cannot be accounted for by
symptomologies associated with the
psychosis itself (i.e., self-injury and
accidental death). This is exactly what was
found by Brown (1997). A final logical
sequel to this idea is that there should be
evidence of oxidative stress in the brains of
schizophrenics caused by a decrease in the
level of available oxygen (which would
cause oxidation in chemical reactions
requiring more oxygen than available). Such
evidence has been found in certain studies of
the brains of schizophrenics after their
deaths (Coyle, 2013).
A final logical sequelae to the putative
model of schizophrenia put forth here is that
the organism afflicted with the traits which
will eventually develop into schizophrenia
should logically increase the chances of
bleeding occurring when the organism is
interfaced with another organism (i.e.,
during pregnancy). This should occur
because of unstable vasculature as a result of
improper vascular responses to reductions in
oxygen. Such increases in the amount of
bleeding during the pregnancy of the
mothers of schizophrenics has been found
by researchers such as Austin (2005). Neural
damage resulting from such bleeding, on the
whole, should be limited, however, due to
such protective factors as the presence of
fetal hemoglobin, which has increased
oxygen carrying capacity compared to
normal hemoglobin (and thus should help to
reduce the probability of ischemic events
occurring in the first place). This fetal
hemoglobin should continue to protect
significantly against damage due to the
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impaired vasodilatory response in
schizophrenics until the third month of life,
when fetal hemoglobin levels reach normal
adult ones (Metaxotou-Mavromati et. al.,
1982).
Limitations and Apparent Inconsistencies
Due to the complex nature of the
schizophrenic disease state, several apparent
inconsistencies between the proposed model
and the current literature on schizophrenia
have been accrued thus far. The main
inconsistency that must be reconciled is that,
as this paper points out, NMDA receptor
antagonists alone are not effective
treatments for schizophrenia (although they
may be effective as adjunct agents). This
seems to provide evidence against the
validity of the proposed model (as well as
against several older models of
schizophrenia) because NMDA receptor
antagonists have been shown to reduce
infarct volume in vivo (Wahlestedt et. al.
1993), and should, by themselves, thus
reduce symptomology progression if this
model is correct. However, NMDA receptor
antagonists alone have a lack of treatment
power in schizophrenia (although they are
used effectively as accessory treatments).
This lack of power can be explained by the
fact that NMDA antagonists cause
excitatory components of neural networks to
become uninhibited, and this in turn can
cause neuronal damage (Onley et. al., 1999).
Because of this, the net amount of protection
conferred by NMDA receptor antagonists
may be limited relative to the efficacy
needed to attenuate symptoms. A second
apparent inconsistency which one may have
noticed is that O'Neil et. al. (1998) found
that dopamine antagonists (like Haloperidol)
were not neuroprotective in rats. This seems
a contradiction to the explanation of the
protective effects of Haloperidol offered
here. However, it is important to note that
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the rats used in that study did not have
dysfunctions of the nitric oxide mediated
pathway for vasodilation. Thus, the O'Neil
study shows that once ischemia has
occurred, dopamine antagonists are not
neuroprotective, however it does not
comment (as the explanation of
Haloperidol's effects does) on the ability of
such agents to prevent ischemia in the first
place.
A limitation of the proposed theory is
that in addition to the HDL increases that
have been shown in schizophrenics, one
would expect low density lipoprotein (LDL)
decreases (as is seen in women taking
oestrogen replacement). This is not seen in
the literature to the knowledge of the author.
This is a limitation of the putative model,
and perhaps future research will illuminate
the mechanisms which prevent the expected
LDL rise. A further limitation of the model
proposed in this paper is if infarct or
ischemia is occurring, then there may be
evidence of abnormally high levels of blood
or traces of blood in the brains of
schizophrenics when examined. This has not
been demonstrated in the literature thus far,
and is a topic that should be examined more
closely in future research. The lack of this
demonstration thus far is should not be taken
as a large mark against the validity of the
model due to the fact that under most of the
current models being used there would be no
reason to look for the presence of blood in
the brains of schizophrenics. Because of
this, many studies which may have found
blood traces may have missed them. A final
limitation of the proposed model is that it,
for the purposes of simplicity in this paper,
does not differentiate between the subtypes
of chronic schizophrenia. This putative
model may not be equally valid for each
subtype, and thus generalization of findings
against or in support of this model between
subtypes should be treated with caution

when applying them to other subtypes of the
disorder (e.g., familial schizophrenia vs.
non-familial types).
Conclusion
In conclusion, several researchers have
predicted that patients with schizophrenia
"may be more susceptible to the
neurophysiological
perturbations
of
environmental experiences that occur in the
context of daily life, as their compensatory
capacity is compromised and more easily
breached. If prolonged or recurrent, such
perturbations can lead to a persistent state of
dysregulation, and potentially enduring
pathologic changes, which are at first
functional and ultimately structural"
(Duncan et. al., 1999). The model proposed
in this paper conforms to these predictions
beautifully, and, to the knowledge of the
author, this putative mechanism has not
been proposed prior to this article. The
considerable (albeit circumstantial) support
for this model (along with its surprising
explanatory power) warrants further
investigation.
Several possible routes for this
investigation are suggested by the discussion
in this paper. For example, one possible
region to focus on in order to find this effect
was inadvertently identified by Rupp et. al.
(2005). In this study, a sub region of the
hippocampus (the subiculum) was identified
that is active only when discriminating
between odors and not during other
olfactory tasks including other olfactory
memory tasks. This area seems like a likely
candidate for damage in schizophrenia as it
would explain the olfactory discrimination
deficits present in the disorder that were
discussed in this paper. Another possible
route for further examination of the
proposed model is that, one could test this
model's prediction that schizophrenics
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should become more vulnerable to the
induction of neural noise over time (i.e., a
prodromal stage schizophrenic less so than
one who has had a chronic form for several
years). This should occur because increases
in the net amount of damage over time
should amplify the underlying pathology of
the dopamine system resulting in unstable
neural representations of stimuli. A second
possible experiment to explore this model's
validity is that schizophrenics with higher
hemoglobin oxygen carrying capacity
should have increased ages of onset of the
disorder and possibly decreased symptom
severity and risk of developing psychosis
(i.e., blood oxygen carrying capacity should
be predictive of whether and how quickly
the onset of schizophrenia occurs in clinical
high risk individuals). This should occur
because higher blood oxygen levels would
help reduce the probability of ischemic
events occurring in the first place.
By exploring this possible ultimate cause
of schizophrenia through experiments such
as these, new and more effective treatments
and early diagnostic tools may be developed
which improve our repertoire of methods
that help to alleviate the immense suffering
caused by this disease.
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